Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will present new findings at the upcoming 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in San Diego. The presentations include Acumen’s recruitment strategies for its Phase 2 ALTITUDE-AD study of sabirnetug, as well as a nonclinical Enhanced Brain Delivery (EBD) study focusing on fusing transferrin receptor binders to sabirnetug to facilitate its transport through the blood-brain barrier. The conference will be held in-person December 1-4, 2025.

Sabirnetug, Acumen’s lead program, is the first humanized monoclonal antibody to demonstrate in early symptomatic AD patients selective target engagement of AβOs, a soluble and highly synaptotoxic form of Aβ that accumulates early in AD and is a persistent trigger of synaptic dysfunction and neurodegeneration. Enrollment in the Phase 2 study of sabirnetug, ALTITUDE-AD, was completed in March 2025.

Additionally, Acumen’s research on EBD was conducted with JCR Pharmaceuticals (“JCR”) as part of its ongoing collaboration announced in July 2025. The goal of this collaboration is to develop a product leveraging Acumen’s AβO-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology – in order to potentially improve drug delivery to the brain and potentially offer patients a more effective treatment option with an improved safety profile, to slow or prevent neurodegeneration associated with AD.

Acumen’s presentation details are as follows:

Topic: P019 ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug in early Alzheimer’s disease

Date/Time: Monday, December 1, 3:00 p.m. - Tuesday, December 2, 5:30 p.m. PST
Format: Poster Presentation
Session: Clinical trials: methodology
Presenting Author: Robyn Moxon, MA, Associate Director, Communications, Acumen Pharmaceuticals

Topic: P381 Fusing Transferrin Receptor Binders to the AβO-targeting Antibody Sabirnetug Achieves Increased Brain Penetration in Mice While Preserving Target Binding

Date/Time: Thursday, December 4, 7:15 a.m. - 5:00 p.m. PST
Format: Poster Presentation
Session: Animal model and Preclinical trials in AD
Presenting Author: Elizabeth Johnson, Ph.D., Senior Bioanalytical Scientist, Acumen Pharmaceuticals

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.